A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette- S.C. Ematologia U
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cacciola, Rossella
NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

Recruiting
N/A
319
Europe
Ropeginterferon alfa-2b, Besremi
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Polycythemia Vera
09/24
12/26
Guglielmelli, Paola
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
MPN-COVID, NCT04385160: Myeloproliferative Neoplasms (MPN) and COVID-19

Recruiting
N/A
552
Europe, US, RoW
Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net
Myeloproliferative Neoplasm, COVID
02/22
08/22
REVIEW, NCT06251102: Real-world Ruxolitinib Experience in PV

Not yet recruiting
N/A
153
NA
Gruppo Italiano Malattie EMatologiche dell'Adulto
Polycythemia Vera
07/25
07/25
ERNEST-3, NCT06533813: Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

Not yet recruiting
N/A
617
Europe, RoW
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline
Myelofibrosis
12/24
12/28
GIMEMA, NCT06657846: HRQoL and Financial Toxicity in Patients with VEXAS Syndrome

Not yet recruiting
N/A
100
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
VEXAS
02/25
06/25

Download Options